Sakshi Batra does a 3-Point Analysis of the earnings fine-print and the outlook on Sequent Scientific.
Only those who can stomach high risks should consider this opportunity
The Bengaluru laboratory was set up in 2017 to cater to the growing analytical requirements of large pharmaceutical and FMCG majors in the region.
Joindre Capital Services is bullish on Sequent Scientific has recommended buy rating on the stock with a target price of Rs 116 in its research report dated April 15, 2019.
Ankara facility is also approved by Saudi FDA and Ethiopian GMP authorities.
The board has declared an interim dividend of 10 percent after a gap of six years, which reflects the confidence for the future, said Manish Gupta, CEO of Sequent Scientific.
The company had posted a net loss of Rs 4.44 crore for the corresponding period of the previous fiscal, Sequent Scientific said in a filing to BSE.
In an interview to CNBC-TV18, Manish Gupta, MD of SeQuent Scientific spoke about the results and his outlook for the company.
SeQuent Scientific has received an establishment inspection report (EIR) from the United States Food and Drug Administration (USFDA) for their animal active pharmaceutical ingredient (API) manufacturing plant at Visakhapatnam. In an interview to CNBC-TV18, Manish Gupta, CEO of the company spoke about the latest happenings in his company and sector.
Alivira has received United States Food and Drug Administration (USFDA) approval for its multi-product animal health active pharmaceutical ingredient (API) facility in Visakhapatnam, SeQuent Scientific said in a filing to the BSE.
"The structuring is directed towards having a sharper focus on compliance, supply chain and front-ends to provide the necessary growth impetus for its consumer facing formulations business," Strides said.
Even as Sequent Scientific is mainly focused on animal health active pharmaceutical ingredients, it is also looking to expand its human health business.
Sequent Scientific has reported a consolidated total income from operations of Rs 176.81 crore and a net loss of Rs 10.25 crore for the quarter ended Jun '16